ACS Fall 2026 First Time Disclosures
The First Time Disclosures sessions at ACS Fall 2026 in Chicago wrapped up with 13 small molecule candidates revealed across two sessions, organised by the MEDI Division and chaired by @[H. Rachel Lagiakos](urn:li:person:IAv8Qvllhb). Quanta Therapeutics opened with QTX3034, a spirocyclic, allosteric G12D-preferring multi-KRAS inhibitor for PDAC and CRC, now showing early monotherapy and cetuximab-combination signals in the clinic. Acerta Pharma/AstraZeneca followed with AZD3632, a menin-KMT2A PPI inhibitor engineered with an atropisomer-stabilising methyl group to clear the M2 muscarinic and hERG liabilities that have dogged earlier menin programmes. Novartis presented the lone degrader of the day, NVP-KFA115, a CRBN-based IKZF2/4 dual degrader built to fix the peripheral neurotoxicity that curtailed its predecessor DKY709. Schrödinger shared SGR-3515 \(INN surbinsertib\), a dual Wee1/Myt1 inhibitor reached through FEP-driven computational design, with early AACR data showing target engagement and stable disease in a majority of evaluable patients. GenFleet Therapeutics disclosed GFH647, a non-covalent BTK inhibitor engineered to hold potency against the resistance-conferring C481S mutation via a Cys481-independent binding mode. Ventus Therapeutics detailed VENT-03 \(iptocigistat\), a cGAS inhibitor now in a Phase 2a study measuring interferon signatures in cutaneous lupus. Pfizer opened the afternoon with PF-07905428, a topical ACC inhibitor for acne, a deliberate pivot away from the systemic exposure issues that limited its earlier oral ACC candidate. Deep Apple Therapeutics presented DAT-003, an MRGPRX2 antagonist designed to block IgE-independent mast cell degranulation while sparing IgE-dependent activation. Blueprint Medicines, now a Sanofi subsidiary, shared BLU-808, a highly selective oral KIT inhibitor now in Phase 2 for chronic urticaria, with reported selectivity exceeding 300-fold over PDGFRA and 9,600-fold over FLT3. Fimbrion Therapeutics, in collaboration with GSK, disclosed GSK3882347, a FimH antagonist offering an anti-virulence route to uncomplicated UTIs rather than conventional antibacterial killing. Maze Therapeutics presented MZE829 \(INN alcedaplin\), an APOL1 inhibitor for APOL1-mediated kidney disease that has since reported a 35.6% mean reduction in urinary albumin-to-creatinine ratio at week 12, rising to 61.8% in the FSGS subgroup. Rectify Pharmaceuticals shared RTY-406, a dual ABCB4/BSEP positive functional modulator for primary sclerosing cholangitis, a disease with no approved therapies. Pfizer closed the sessions with PF-07976016, a GIPR antagonist for obesity intended to complement GLP-1R agonism. Thank you to the ACS organising committee for an excellent set of sessions. Which molecule inspired you most from the 2026 First Time Disclosures?